Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era
- PMID: 24557576
- PMCID: PMC4119507
- DOI: 10.1007/s10620-014-3065-y
Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era
Abstract
Porto-pulmonary hypertension (POPH), once considered an absolute contraindication for liver transplantation (LT), has become a more accepted indication because of the evolution of treatment with prostacyclin analogues, phosphodiesterase inhibitors and endothelin receptor antagonists. An exception model for end stage liver disease (MELD) score of 22 is assigned to candidates with documentation of effective treatment. We examined the post-transplant outcomes of patients who received LT for POPH with exception.
Methods: Scientific Registry of Transplant Recipients data on 34,318 adult (≥ 18 years) deceased donor LT recipients transplanted between March 1, 2002 and August 31, 2010 were reviewed. The diagnosis of POPH was ascertained from MELD exception forms. Patients were followed from the time of transplant until the earlier occurrence of death or end of the follow-up period. Cox regression was used to evaluate the predictors of post-LT mortality and graft failure.
Results: During the study period, 34,318 patients received deceased donor LT. Seventy eight out of 34,318 patients were transplanted for POPH with MELD exception. The 1-year adjusted risks of patient death and graft failure for patients transplanted under exception rules for POPH were significantly higher than with POPH adult recipients who did not receive exception points (death:hazard ratio [HR] = 2.25, p = 0.005 and graft failure HR = 1.96, p = 0.012).
Conclusions: This study of national data suggests that treated POPH continues to be associated with inferior early post-transplant outcomes.
Figures



Similar articles
-
Comparison of Post-Liver Transplantation Outcomes in Portopulmonary Hypertension and Pulmonary Venous Hypertension: A Single-Center Experience.Transplant Proc. 2017 Mar;49(2):338-343. doi: 10.1016/j.transproceed.2016.12.006. Transplant Proc. 2017. PMID: 28219595
-
Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception.Liver Transpl. 2022 Jul;28(7):1224-1230. doi: 10.1002/lt.26422. Epub 2022 Apr 21. Liver Transpl. 2022. PMID: 35106916 Review.
-
Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.Liver Transpl. 2021 Dec;27(12):1811-1823. doi: 10.1002/lt.26091. Epub 2021 Jun 29. Liver Transpl. 2021. PMID: 33964116 Free PMC article.
-
Portopulmonary hypertension: Still an appropriate consideration for liver transplantation?Liver Transpl. 2016 Dec;22(12):1637-1642. doi: 10.1002/lt.24625. Epub 2016 Nov 5. Liver Transpl. 2016. PMID: 27593213
-
Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward.J Hepatol. 2013 Aug;59(2):367-74. doi: 10.1016/j.jhep.2013.03.026. Epub 2013 Apr 1. J Hepatol. 2013. PMID: 23557870 Review.
Cited by
-
The Intersection of Pulmonary Hypertension and Solid Organ Transplantation.Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4 Suppl):10-13. doi: 10.14797/mdcj-12-4s1-10. Methodist Debakey Cardiovasc J. 2016. PMID: 28298957 Free PMC article. Review.
-
The early outcomes of candidates with portopulmonary hypertension after liver transplantation.BMC Gastroenterol. 2018 Jun 7;18(1):79. doi: 10.1186/s12876-018-0797-8. BMC Gastroenterol. 2018. PMID: 29879915 Free PMC article.
-
Predictors of Waitlist Mortality in Portopulmonary Hypertension.Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666. Transplantation. 2017. PMID: 28207639 Free PMC article.
-
Hemodynamic and Clinical Response to Liver Transplantation in Children and Young Adults POPH Patients.Pediatr Cardiol. 2024 Jun;45(5):1142-1150. doi: 10.1007/s00246-023-03121-0. Epub 2023 Feb 8. Pediatr Cardiol. 2024. PMID: 36754885
-
Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.Curr Gastroenterol Rep. 2016 Jun;18(6):29. doi: 10.1007/s11894-016-0504-2. Curr Gastroenterol Rep. 2016. PMID: 27098816 Review.
References
-
- Bandara M, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl. 2010;16(8):983–9. - PubMed
-
- Krowka MJ, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10(2):174–82. - PubMed
-
- Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl. 2005;11(9):1026–7. - PubMed
-
- Martinez-Palli G, et al. Liver transplantation in high-risk patients: hepatopulmonary syndrome and portopulmonary hypertension. Transplant Proc. 2005;37(9):3861–4. - PubMed
-
- Krowka MJ, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30(3):641–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical